IRS Expands Tax Breaks for Tech and Pharma in New Legislation

Feb 19, 2026, 2:42 AM

Hover over text to view sources

The Internal Revenue Service (IRS) has recently implemented significant tax breaks for technology and pharmaceutical companies, as part of the broader fiscal policies outlined in the One Big Beautiful Bill Act (OBBBA) signed into law by former President Donald Trump on July 4, 2025. This legislation aims to stimulate economic growth through enhanced tax incentives, particularly for research and development (R&D) initiatives, which are crucial in these rapidly evolving industries.

One of the key features of the OBBBA is the provision that allows companies to immediately deduct R&D expenses rather than amortizing them over time. This change is particularly beneficial for tech and pharmaceutical firms, as it enables them to reduce their taxable income in the year the expenses are incurred, thereby improving cash flow and encouraging further investment in innovation. The ability to write off these costs immediately is expected to enhance the financial viability of cutting-edge projects, which can often require substantial upfront investment.

In addition to the immediate R&D deductions, the OBBBA reinstates 100% first-year bonus depreciation for qualified property, which includes machinery and equipment used in R&D processes. This provision is intended to incentivize companies to invest in new technology and infrastructure, further supporting growth in the tech and pharma sectors. The legislation also increases the Section 179 deduction cap from $1 million to $2.5 million, allowing businesses to deduct the full cost of certain investments in the year they are made.

Moreover, the OBBBA has made significant changes to the treatment of qualified small business stock (QSBS), which may affect startups in the tech sector. The legislation reduces the required holding period for QSBS benefits from five years to three years, thereby allowing investors to realize tax advantages more quickly and encouraging investment in new ventures.

The expansion of tax breaks is not without its critics. Some experts argue that these provisions primarily benefit wealthy corporations and could deepen economic inequalities. The Congressional Budget Office (CBO) has estimated that the OBBBA will add approximately $2.8 trillion to the national debt by 2034, raising concerns about long-term fiscal sustainability. Critics also highlight that while the legislation aims to stimulate growth, it may exacerbate existing disparities, particularly among lower-income populations who may not directly benefit from corporate tax cuts.

Advocates of the tax breaks argue that by fostering innovation in the tech and pharmaceutical sectors, the legislation will ultimately lead to job creation and economic growth. They contend that supporting R&D is essential for maintaining competitiveness in an increasingly global market, particularly as other countries ramp up their own investment in technology and healthcare innovation.

As the IRS begins to implement these tax provisions, companies in the tech and pharmaceutical industries are poised to benefit significantly. The immediate deductions for R&D expenses and the reinstatement of bonus depreciation are likely to encourage further investment in innovation, which is critical for addressing challenges in healthcare and technology advancement.

In conclusion, the recent IRS tax break expansions for the tech and pharmaceutical industries, as part of the OBBBA, reflect a strategic effort to bolster US competitiveness in key sectors. While the potential benefits of increased investment and innovation are clear, the implications for overall fiscal health and economic equity continue to provoke debate among policymakers and economists alike.

Jury Holds Meta and Google Liable for Social Media Addiction

A California jury has found Meta and Google negligent in a landmark trial concerning the mental health impacts of their social media platforms on young users. The verdict, which awarded $6 million to the plaintiff, marks a significant step in holding tech companies accountable for the design of addictive features in their applications.

Trump's Science Funding Cuts Threaten U.S. Research Landscape

The Trump administration's cuts to federal funding for science and research are jeopardizing critical projects and prompting a potential brain drain of talent from the US Universities are struggling to maintain their research efforts, with many young scientists considering opportunities abroad. The long-term implications for American scientific advancement could be severe.

Trump's FY27 Budget Cuts Public Health for War Funding and Tax Breaks

Former President Donald Trump's FY2027 budget proposal has raised alarm due to its severe cuts to public health priorities, jeopardizing essential health services and research funding. Critics argue the budget prioritizes military spending and tax breaks for the wealthy over the health of American citizens.

Mental Health Workers Demand AI Protections Amid Strikes in California

Mental health workers in California are on strike, advocating for protections against the increasing use of artificial intelligence (AI) in patient care at Kaiser Permanente. They argue that unregulated AI could threaten jobs and compromise patient safety, prompting calls for legislative action and cross-union solidarity.

Meta and Google Found Liable for Social Media Harms to Kids

A Los Angeles jury has ruled that Meta and Google are liable for the mental distress caused to a teenager by their platforms, awarding $3 million in damages. The case highlights concerns about social media addiction and its impact on young users, potentially paving the way for further legal actions against tech giants.